OncoMatch/Clinical Trials/NCT06776250
Study of How Safe and Effective Tarlatamab is in Brain Cancers
Is NCT06776250 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tarlatamab for astrocytic tumor.
Treatment: Tarlatamab — This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: IDH1 mutation
Required: IDH2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: tarlatamab (tarlatamab)
Any previous treatment with tarlatamab
Cannot have received: conventional or investigational anticancer therapy
Receipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of tarlatamab
Cannot have received: systemic chemotherapy
Patients receiving any systemic chemotherapy or radiotherapy within 28 days prior to study treatment
Cannot have received: radiotherapy
Patients receiving any systemic chemotherapy or radiotherapy within 28 days prior to study treatment
Lab requirements
Blood counts
normal organ and bone marrow function measured within 14 days prior to administration of study treatment
Kidney function
normal organ and bone marrow function measured within 14 days prior to administration of study treatment
Liver function
normal organ and bone marrow function measured within 14 days prior to administration of study treatment
Patients must have normal organ and bone marrow function measured within 14 days prior to administration of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify